Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · QuidelOrtho (QDEL)

QuidelOrtho Q3 revenue fell 12% to $619 million; 2026 adjusted EPS range lowered

Negative Impact 4 of 5 earnings

QuidelOrtho reported third-quarter 2026 revenue of $619 million, down 12% from the prior year, and a GAAP net loss of $54 million, or $0.78 per diluted share. The company lowered its top-end 2026 guidance for adjusted diluted EPS to $0.65 to $0.70 from $0.65 to $0.90, and launched a restructuring program it expects to save over $80 million a year in 2027, with $30 million to $35 million in one-time charges in the fourth quarter of 2026.

Key points

  • Q3 2026 revenue $619 million, down 12%; Point of Care revenue fell 27% on a softer respiratory season
  • Q3 GAAP net loss $54 million ($0.78 per share); adjusted diluted EPS $0.31
  • 2026 guidance: revenue $2.52 to $2.54 billion; adjusted EBITDA $540 to $545 million; adjusted EPS $0.65 to $0.70 (previously $0.65 to $0.90)
  • Effective November 9, 2026, Chief Operations Officer Phil McLellan's role is eliminated; Jonathan Siegrist and Bryan Hanson named heads of the two new businesses

The filing

CompanyQuidelOrtho (QDEL)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:09 PM ET
Accession number0001906324-26-000040

Items reported: 2.02 Results of Operations5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.